Sub-acute toxicity of the standardised extract of Boesenbergia rotunda in rats DOI Open Access

Pinnakarn Techapichetvanich,

Phisit Khemawoot,

Passaraporn Srimangkornkaew

et al.

ScienceAsia, Journal Year: 2024, Volume and Issue: 50(3), P. 1 - 1

Published: Jan. 1, 2024

An in vitro study of Thai medicinal plants revealed anti-SARS-CoV-2 activity ethanolic extract Boesenbergia rotunda and its bioactive component panduratin A. The present aims to evaluate the safety after 28 consecutive days oral doses according OECD GLP 407.The 28-day repeated were performed both male female Wistar rats.Three 150, 300 600 mg/kg/day assigned as low, medium high doses, respectively.During administration period, there was no evidence morbidity, mortality, or neurological toxicity for gender all doses.Weight food water intake similar control group.The hematological clinical biochemistry parameters within normal ranges rats.The oestrous cycle animals groups vaginal cytology investigation showed abnormal cellular types.The statistically significant difference weight organs no-test itemrelated effects histopathological examination remarkable lesion.The observed adverse effect level (NOAEL) B. considered be mg/kg body per day.These findings are useful information developing a potential phytopharmaceutical product future investigation.

Language: Английский

Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study) DOI Creative Commons
Ivan Gentile, Riccardo Scotto,

Maria Michela Scirocco

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(3), P. 669 - 669

Published: March 15, 2025

We conducted a real-life case–control study among outpatients with Omicron SARS-CoV-2 infection to assess the effectiveness of molnupiravir (MNP) in reducing hospital admission, admission intensive care unit, and death at day 28. Cases were SARS-CoV-2-positive patients seeking medical within five days symptom onset from 1 January 31 December 2022, who received MNP. Controls selected regional database positive subjects did not receive antiviral treatment for SARS-CoV-2. A total 1382 included (146 cases, 1236 controls). Vaccinated had lower risk mortality composite outcome (hospital ICU or all-cause death) than unvaccinated ones (0.6% vs. 7.8%, p < 0.001 2% = 0.001, respectively). After full-matching propensity score analysis, MNP-treated incidence outcome, although no effect was observed on individual outcomes. In subgroup analyses by vaccination status, MNP effective preventing all outcomes reduced both vaccinated patients. Molnupiravir effectively infection, more pronounced benefit These findings highlight MNP’s potential help prevent disease progression high-risk patients, thereby supporting its role as an outpatient therapeutic option COVID-19.

Language: Английский

Citations

1
Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan DOI Creative Commons
Akira Yuasa, Hiroyuki Matsuda, Yosuke Fujii

et al.

Journal of health economics and outcomes research, Journal Year: 2025, Volume and Issue: unknown, P. 75 - 85

Published: Jan. 1, 2025

Background: Nirmatrelvir/ritonavir (NMV/r) and molnupiravir are oral antiviral drugs approved for the treatment of early symptomatic patients with mild to moderate COVID-19 at high risk progression severe disease in Japan. Objective: This study evaluated, from a Japanese payer perspective, cost-effectiveness NMV/r compared among COVID-19. Methods: model describes history impact on short-term long-term outcomes. was molnupiravir, scenario analysis standard care over lifetime horizon. Results: When showed higher quality-adjusted life years (QALYs) (15.752 vs 15.739) total cost (¥6 248 014 ¥6 245 829 [US $44 136.86 121.42]). The incremental ratio ¥164 934 (US $1165.12) per QALY gained, which lower than willingness-to-pay (WTP) threshold Japan (¥5 000 000/QALY $35 320.71/QALY]). In analysis, ¥3 646 821 $25 761.66) gained. One-way sensitivity probabilistic that cost-effective consistently. All results one-way ratios were below WTP result acceptability curve probability ¥5 320.71/QALY) 100.00%. Conclusion: is perspective. provides evidence

Language: Английский

Citations

0
Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan DOI Creative Commons
Akira Yuasa, Hiroyuki Matsuda, Yosuke Fujii

et al.

Journal of health economics and outcomes research, Journal Year: 2025, Volume and Issue: 12(1)

Published: Feb. 24, 2025

Background: Nirmatrelvir/ritonavir (NMV/r) and molnupiravir are oral antiviral drugs approved for the treatment of early symptomatic patients with mild to moderate COVID-19 at high risk progression severe disease in Japan. Objective: This study evaluated, from a Japanese payer perspective, cost-effectiveness NMV/r compared among COVID-19. Methods: model describes history impact on short-term long-term outcomes. was molnupiravir, scenario analysis standard care over lifetime horizon. Results: When showed higher quality-adjusted life years (QALYs) (15.752 vs 15.739) total cost (¥6 248 014 ¥6 245 829 [US $44 136.86 121.42]). The incremental ratio ¥164 934 (US $1165.12) per QALY gained, which lower than willingness-to-pay (WTP) threshold Japan (¥5 000 000/QALY $35 320.71/QALY]). In analysis, ¥3 646 821 $25 761.66) gained. One-way sensitivity probabilistic that cost-effective consistently. All results one-way ratios were below WTP result acceptability curve probability ¥5 320.71/QALY) 100.00%. Conclusion: is perspective. provides evidence

Language: Английский

Citations

0
Leveraging SARS-CoV-2 Main Protease (Mpro) for COVID-19 Mitigation with Selenium-Based Inhibitors DOI Open Access
Viviana De Luca, Andrea Angeli, Alessio Nocentini

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(2), P. 971 - 971

Published: Jan. 12, 2024

The implementation of innovative approaches is crucial in an ongoing endeavor to mitigate the impact COVID-19 pandemic. present study examines strategic application SARS-CoV-2 Main Protease (M

Language: Английский

Citations

2
Nirmatrelvir: From Discovery to Modern and Alternative Synthetic Approaches DOI Open Access
Michela Galli,

Francesco Migliano,

Valerio Fasano

et al.

Processes, Journal Year: 2024, Volume and Issue: 12(6), P. 1242 - 1242

Published: June 17, 2024

The global urgency in response to the COVID-19 pandemic has catalyzed extensive research into discovering efficacious antiviral compounds against SARS-CoV-2. Among these, Nirmatrelvir (PF-07321332) emerged as a promising candidate, exhibiting potent activity by targeting main protease of SARS-CoV-2, and been marketed combination with ritonavir first oral treatment for name PaxlovidTM. This review outlines synthetic approaches Nirmatrelvir, ranging from Pfizer’s original method newer, more sustainable strategies, such flow chemistry strategies multicomponent reactions. Each approach’s novelty contributions yield purification processes are highlighted. Additionally, synthesis key fragments comprising innovative optimization discussed.

Language: Английский

Citations

2
Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients DOI
Chiara Sepulcri, Claudia Bartalucci, Małgorzata Mikulska

et al.

Current Opinion in Infectious Diseases, Journal Year: 2024, Volume and Issue: 37(6), P. 506 - 517

Published: Oct. 23, 2024

Purpose of review The purpose this is to report the available evidence regarding use combination regimens antivirals and/or antibody-based therapy in treatment SARS-CoV-2 immunocompromised patients. Recent findings Literature search identified 24 articles, excluding single case reports, which included mainly patients with hematological malignancies B-cell depletion. Data were divided based on timing and reason for administration treatment, that is, early prevent progression severe COVID-19 prolonged or relapsed infection. We described treated populations, duration composition treatment. briefly addressed new options we proposed an algorithm management infection affected by malignancies. Summary Combination seems effective (73–100%) well tolerated (<5% reported bradycardia, hepatotoxicity, neutropenia) strategy treating prolonged/relapsed infections host, although its optimal cannot be defined currently evidence. role as at a high risk disease/persistent shedding requires further from comparison monotherapy, even though efficacy was combinations plus mAbs previous viral variants.

Language: Английский

Citations

2
Sub-acute toxicity of the standardised extract of Boesenbergia rotunda in rats DOI Open Access

Pinnakarn Techapichetvanich,

Phisit Khemawoot,

Passaraporn Srimangkornkaew

et al.

ScienceAsia, Journal Year: 2024, Volume and Issue: 50(3), P. 1 - 1

Published: Jan. 1, 2024

An in vitro study of Thai medicinal plants revealed anti-SARS-CoV-2 activity ethanolic extract Boesenbergia rotunda and its bioactive component panduratin A. The present aims to evaluate the safety after 28 consecutive days oral doses according OECD GLP 407.The 28-day repeated were performed both male female Wistar rats.Three 150, 300 600 mg/kg/day assigned as low, medium high doses, respectively.During administration period, there was no evidence morbidity, mortality, or neurological toxicity for gender all doses.Weight food water intake similar control group.The hematological clinical biochemistry parameters within normal ranges rats.The oestrous cycle animals groups vaginal cytology investigation showed abnormal cellular types.The statistically significant difference weight organs no-test itemrelated effects histopathological examination remarkable lesion.The observed adverse effect level (NOAEL) B. considered be mg/kg body per day.These findings are useful information developing a potential phytopharmaceutical product future investigation.

Language: Английский

Citations

0